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Abstract: Pain is experienced by most cancer patients and represents an important issue in 
the clinical setting. Breakthrough pain is a transitory ﬂ  are of pain that occurs in most cancer 
patients on a background of otherwise controlled persistent pain. Treatment of breakthrough 
pain is a challenging phenomenon. Oral transmucosal fentanyl citrate (OTFC; Actiq®, Cephalon, 
UK), a new opioid formulation with a unique delivery system, utilizing the advantages that 
nanotechnology offers, reﬂ  ects the characteristics of breakthrough pain (rapid onset of action 
and short duration), which makes it an effective treatment to cancer patients who are already 
receiving opioids and continue to experience such ﬂ  ares of pain. Oral transmucosal fentanyl 
citrate is speciﬁ  cally developed and approved for the management of breakthrough pain in 
cancer patients and it has the potential to be a useful tool for clinicians.  
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Introduction
Pain is often an undertreated symptom in cancer and highly affects patients’ qual-
ity of life. Seventy-four percent of patients with advanced cancer report pain which 
is usually controlled in these patients sufﬁ  ciently with a ﬁ  xed-scheduled, around-
the-clock opioid regimen. Apart from this chronic and persistent pain, up to two thirds 
of patients also experience transient ﬂ  ares of severe pain that occur on a background of 
otherwise controlled and tolerated chronic pain (Portenoy and Hagen 1990; Portenoy 
et al 1999a). These transitory ﬂ  ares are commonly described as “breakthrough pains” 
and are characterized by rapid onset (within 3 minutes), moderate to severe intensity, 
and relatively short duration (average 30 minutes) (Portenoy et al 1993; Simmonds 
1999; McMenamin and Farrar 2002). Moreover, breakthrough pain is associated with 
more severe pain, higher distress, and lower quality of life (Portenoy et al 1999b; 
Hwang et al 2003). 
Nanotechnology is a multidisciplinary ﬁ  eld involving the design and engineering 
of objects <500 nanometers (nm) in size. Over the last two decades, nanotechnology 
has offered a variety of nanoscale tools speciﬁ  cally designed for therapeutic use in 
cancer. For drug-delivery systems, nanotechnology offers the potential to optimize drug 
delivery and minimize side-effects. Recently, novel nanotechnology-based methods, 
such as implantable drug delivery devices, and transdermal and transmucosal delivery 
systems, have been engineered (Csaba et al 2006). Oral transmucosal drug delivery 
is a method of systemic drug delivery that offers several advantages over traditional 
parenteral or enteral methods (Sprintz et al 2005; Cuenca et al 2006).
Nanotechnology and cancer pain
Moderate to severe pain is experienced by one third of cancer patients receiving active 
therapy and by 60%–90% of patients with advanced disease (Daut and Cleeland 1982; International Journal of Nanomedicine 2007:2(1) 50
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Twycross and Fairﬁ  eld 1982). Advances in the diagnosis and 
treatment of cancer, coupled with advances in our understand-
ing of anatomy, physiology, pharmacology, and pain percep-
tion, have led to improved care of the patient with pain (Foley 
1999). Such patients are managed most effectively by the use 
of many analgesic agents, such as opioids, non-steroidal anti-
inﬂ  ammatory drugs, and corticosteroids, in the form of pill, 
oral solution, or injection, providing additional beneﬁ  t in the 
adjuvant setting. Opioid analgesics remain the cornerstone 
of pharmacotherapy for pain, with morphine long being 
the gold standard for cancer-associated pain. Short-lived 
drugs are generally favored because they are easier to titrate 
than those with a long half-life. The optimal route of adminis-
tration of opioids is oral; however, bowel obstruction, severe 
vomiting, or coma may preclude this route. 
Breakthrough pain is a transitory ﬂ  are of pain that occurs 
in most cancer patients on a background of otherwise con-
trolled persistent pain. Treatment of breakthrough pain is a 
challenging phenomenon. In cancer patients, immediate 
release, short-acting oral opioids, such as morphine sulfate, 
oxycodone, and hydromorphone, taken as needed, are com-
monly used to treat breakthrough pain. 
Nanotechnology has exhibited a remarkable progress 
over the past 20 years in the management of pain in cancer 
patients. Recent applications at the nanoscale level include 
novel drug-delivery systems, such implantable drug-delivery 
devices, transdermal or transmucosal patches, and micro-
needles. Oral transmucosal fentanyl citrate (OTFC; Actiq®, 
Cephalon, UK) is the ﬁ  rst medication developed speciﬁ  -
cally for the treatment of breakthrough pain and provides 
its active ingredient, fentanyl, in a unique oral transmucosal 
delivery system, utilizing microfabrication technology, 
offering personal pain control for cancer patients 
(Mystakidou et al 2006).
Oral transmucosal fentanyl citrate 
and cancer pain
Oral transmucosal fentanyl citrate is a solid formulation of 
fentanyl citrate, a potent (50- to 100-fold as potent as mor-
phine), short-acting, rapid-onset, lipophilic, synthetic opioid 
with selective activity for μ-receptors expressed in the brain, 
spinal cord, and other tissues. OTFC is formulated as a solid 
drug matrix on a handle allowing the rotation of the unit in 
the mouth for optimal absorption and the removal of the unit 
if signs of excessive opioid effects occur during administra-
tion. OTFC is available in six strengths equivalent to 200, 
400, 600, 800, 1200, or 1600 μg fentanyl base.
Fentanyl, a pure opioid agonist, acts primarily through 
interaction with opioid μ-receptors located in the brain, 
spinal cord, and smooth muscle. The primary site of thera-
peutic action is the central nervous system (CNS) (Portenoy 
et al 1993; Mystakidou 2002). The most clinically useful 
pharmacological effects of the interaction of fentanyl with 
μ-receptors are analgesia and sedation. Other opioid effects 
may include somnolence, hypoventilation, bradycardia, pos-
tural hypotension, pruritus, dizziness, nausea, diaphoresis, 
ﬂ  ushing, euphoria, and confusion or difﬁ  culty in concentrat-
ing at clinically relevant doses.
In the clinical setting, pharmacological and pharma-
cokinetic differences have been observed between patients 
administered fentanyl. The variable binding of serum fen-
tanyl to plasma proteins may be a factor in these observed 
differences. Approximately 80% of fentanyl is bound to 
plasma proteins (Mather 1983), such as the acute phase 
protein α1-acid glycoprotein (Meuldermans et al 1982), 
with only free fentanyl able to cross the blood–brain bar-
rier. Variability in cerebrospinal ﬂ  uid concentrations of 
endogenous opioids may also contribute to these observed 
differences (Cohen et al 1982; Tamsen et al 1982). The 
requirement for higher than estimated blood concentra-
tions typically sufficient to elicit clinically significant 
analgesia (~1 ng/mL) may result in ventilatory depres-
sion (at >2 ng/mL) (Cartwright et al 1983). This need for 
additional supportive analgesia without severe respiratory 
depression led to the development of the oral transmucosal 
fentanyl delivery system.
This delivery approach offers simple, tolerable, and 
patient-compliant administration of fentanyl for rapid onset 
of opioid analgesia speciﬁ  cally for breakthrough pain epi-
sodes associated with cancer. The OTFC delivery system 
incorporates nanoparticle technology for the improvement 
of transmucosal transport of fentanyl. The achievement of 
high surface-volume ratios of nanosized drug maximizes 
drug–mucosal interactions and thus increases the bioavail-
ability of fentanyl compared with the drug administered in 
larger particles (Csaba et al 2006).
The absorption pharmacokinetics of fentanyl from the 
oral transmucosal dosage form is a combination of an initial 
rapid absorption from the buccal mucosa and a more pro-
longed absorption of swallowed fentanyl from the gastroin-
testinal tract (Streisand et al 1991). Both the blood fentanyl 
proﬁ  le and the bioavailability of fentanyl will vary depending 
on the fraction of the dose that is absorbed through the oral 
mucosa and the fraction swallowed. International Journal of Nanomedicine 2007:2(1) 51
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Normally, approximately 25% of the total dose of OTFC 
is rapidly absorbed from the buccal mucosa and becomes 
systemically available. The remaining 75% of the total dose 
is swallowed with the saliva and then is slowly absorbed from 
the gastrointestinal tract. About one third of this amount (25% 
of the total dose) escapes hepatic and intestinal ﬁ  rst-pass 
elimination and becomes systemically available. Thus, the 
generally observed 50% bioavailability of OTFC is divided 
equally between rapid transmucosal and slower gastrointes-
tinal absorption.
Dose proportionality among four of the available 
strengths of OTFC (200, 400, 800, and 1600 μg) has been 
demonstrated in a balanced crossover design in adult subjects 
(Streisand et al 1998). Mean serum fentanyl levels following 
these four doses of OTFC are shown in Figure 1. The curves 
for each dose level are similar in shape, with increasing dose 
levels producing increasing serum fentanyl levels.
The pharmacokinetic parameters of the four strengths 
of OTFC tested in the dose-proportionality study are shown 
in Table 1. The mean Cmax ranged from 0.39 to 2.51 ng/mL 
(Streisand et al 1998). The median time of maximum plasma 
concentration (Tmax ) across these four doses of OTFC varied 
from 20 to 40 minutes (range of 20–480 minutes) as meas-
ured after the start of administration. Moreover, studies in 
healthy donors showed that two smaller doses of OTFC 
(400 μg) administered simultaneously are pharmacokineti-
cally equivalent to an identical dose administered as a single 
unit (800 μg) (Lee et al 2003).
Fentanyl is principally (more than 90%) metabolized 
in the liver and in the intestinal mucosa by the cytochrome 
P450 3A4 isoenzyme system by oxidative N-dealkylation to 
norfentanyl and other inactive metabolites. Less than 7% of 
the dose is excreted unchanged in the urine, and only about 
1% is excreted unchanged in the feces. The metabolites 
are mainly excreted in the urine, while fecal excretion is 
less important. The total plasma clearance of fentanyl is 
0.5 L/h/kg (range 0.3–0.7 L/h/kg). The terminal elimina-
tion half-life after OTFC administration is about 7 hours 
(Cephalon Inc. 2003; Mystakidou et al 2005). The structural 
formula of the compound is shown in Figure 2.
OTFC for the management of breakthrough pain has been 
evaluated in small, short-term studies in adult patients with 
cancer-related pain. In these studies, patients were either 
taking an oral opioid (usually morphine) or transdermal 
fentanyl as their around-the-clock medication to control their 
persistent pain. Two randomized, double-blind, dose titration 
studies of OTFC have been published (n = 65, 62) (Christie 
et al 1998; Portenoy et al 1999a). The results demonstrated 
that 74% and 76% of patients, respectively, were able to iden-
tify a safe and effective dose of OTFC. The mean successful 
dose of OTFC in these studies was approximately 600 μg. 
No relationship was found between the successful dose of 
OTFC and the total daily dose of around-the-clock opioid in 
either study, indicating that the optimal dose of OTFC cannot 
be predicted by the total daily dose of ﬁ  xed-schedule opioid. 
Additionally, OTFC was reported to produce a greater anal-
gesic effect, better global satisfaction, and a more rapid onset 
of action than the usual breakthrough medication (Christie 
et al 1998; Portenoy et al 1999a).
The efﬁ  cacy of OTFC has been evaluated in one ran-
domized, placebo-controlled trial and one randomized 
comparative study with immediate-release morphine 
sulphate (MSIR) (Farrar et al 1998; Coluzzi et al 2001). 
The placebo-controlled study was a multicenter, crossover 
study that evaluated the efﬁ  cacy of individualized doses of 
OTFC. A total of 130 patients who met the eligibility criteria 
underwent open-label dose titration to identify their successful 
dose. Ninety-two patients successfully completed the dose 
titration phase and consented to participate in the randomized, 
double-blind phase during which each patient acted as his/her 
own control. Each patient was given 10 units: 7 were OTFC 
at the same dose found effective for that patient in the titra-
tion phase and 3 were identically formulated placebo. All 
10 doses were to be taken within a 14-day period. Patients 
were allowed to take a dose of their usual rescue medication 
if adequate pain relief was not achieved after 30 minutes. 
Patients completed a medication diary at 0, 15, 30, 45, and 
60 minutes following consumption of a unit. In the primary 
efﬁ  cacy analysis (excluding protocol violations; n = 86) 
analgesic effect in terms of pain intensity difference (the 
difference in pain intensity immediately before consumption 
of trial medication and at 15, 30, 45, and 60 minutes post 
consumption) and pain relief was signiﬁ  cantly greater with 
OTFC than placebo for all time points (p < 0.0001). The 
mean global performance evaluation values also signiﬁ  cantly 
favored OTFC (p < 0.0001). Patients required signiﬁ  cantly 
more additional rescue medication for breakthrough pain 
episodes treated with placebo than for episodes treated 
with OTFC; 34% vs 15%; RR = 2.27 (95% CI: 1.51–3.26), 
p < 0.0001 (Farrar et al 1998).
The comparative study was a randomized, double-blind, 
crossover study assessing the efﬁ  cacy of successful doses of 
OTFC with MSIR. Initially 134 patients who met the eligibil-
ity criteria and were using a successful dose of 15 mg, 30 mg, International Journal of Nanomedicine 2007:2(1) 52
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45 mg, or 60 mg MSIR were entered into an open-label dose 
titration phase to identify a successful dose of OTFC. Ninety-
three of these patients successfully completed the titration 
phase and entered the randomized, double-blind phase during 
which each patient acted as his/her own control. Each patient 
was given 10 sets of medication (5 contained OTFC + placebo 
capsules; 5 contained placebo units + MSIR capsules). The 
patient consumed a full set of study medication at each episode 
of breakthrough pain, with all 10 doses to be taken within a 
14-day period. In the primary efﬁ  cacy analysis (for patients 
who had at least one evaluable episode for each study drug; n 
= 75) OTFC was statistically signiﬁ  cantly superior to MSIR 
in terms of pain intensity difference (p < 0.008) and pain relief 
(p < 0.009) at each time point, and global performance rating 
(p < 0.001). In addition, signiﬁ  cantly (p < 0.001) more pain 
episodes treated with OTFC had a greater than 33% change 
in pain intensity at 15 minutes than MSIR, implying a faster 
onset of action with OTFC (Coluzzi et al 2001). Another open-
label study evaluated the long-term safety and tolerability of 
OTFC in ambulatory cancer patients with breakthrough pain 
(Payne et al 2001). Patients had participated in a previous 
short-term titration trial of OTFC, were experiencing at least 
one episode per day of breakthrough pain, and had achieved 
relief of their breakthrough pain with an opioid. In total, 
41 766 units of OTFC were used to treat 38 595 episodes 
of breakthrough pain in 155 patients. Patients averaged 2.9 
breakthrough pain episodes per day. About 92% of episodes 
were successfully treated with OTFC and there was no trend 
toward decreased effectiveness over time. Most patients (61%) 
did not require dose escalation during treatment. Global sat-
isfaction ratings were consistently above 3 (0 = poor through 
4 = excellent), indicating very good to excellent relief. Com-
mon adverse events associated with OTFC were somnolence 
(9%), constipation (8%), nausea (8%), dizziness (8%), and 
Table 1 The pharmacokinetic parameters of the four strengths of OTFC (200, 400, 800, and 1600 μg) tested in the dose-proportionality 
study. Reproduced with permission from Cephalon Inc. (2003)
Pharmacokinetic parameter   200 μg   400 μg 800  μg 1600  μg
Tmax , minute median (range)   40 (20–120)   25 (20–240)   25 (20–120)   20 (20–480) 
Cmax , ng/mL mean (% CV)   0.39 (23)   0.75 (33)   1.55 (30)   2.51 (23) 
AUC0-1440 , ng/mL minute mean (% CV)   102 (65)   243 (67)   573 (64)   1026 (67) 
t½ , minute mean (% CV)   193 (48)   386 (115)   381 (55)   358 (45) 
Figure 1 Mean serum fentanyl levels following administration of the four strengths of OTFC (200, 400, 800, and 1600 μg) in adult subjects. Reproduced with permission 
from Cephalon Inc. (2003).
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vomiting (5%). Six patients (4%) discontinued therapy due 
to an OTFC-related adverse event. There were no reports of 
abuse and no concerns about the safety of the drug raised by 
patients or families. OTFC was used safely and effectively 
during long-term treatment of breakthrough pain in cancer 
patients at home. 
Finally, a recent study evaluated the efﬁ  cacy of OTFC 
in the outpatient management of severe cancer patient crises 
(Burton et al 2004). Prior to OTFC treatment, all patients 
reported a mean pain intensity of 9.0 (SD = 1.2). After OTFC 
treatment, patients reported a mean intensity of 3.0 (SD = 1.4), 
a signiﬁ  cant reduction in pain intensity (p < 0.001). In most 
cases, OTFC averted the need for an emergency center visit, 
parenteral opioids, and hospital admission, which suggests 
that OTFC could be an effective alternative over intravenous 
opioids to rapidly titrate analgesia in selected opioid-tolerant 
cancer patients experiencing severe pain.
Conclusions
The integration of nanotechnology into cancer therapeutics, 
including the management of breakthrough pain in cancer 
patients, is a rapidly developing ﬁ  eld which will dramati-
cally change medical practice in future years. Numerous 
data accentuate the great potential of nanosized transmucosal 
delivery systems and their promising future in the clinical 
setting. Oral transmucosal drug delivery of fentanyl citrate 
for the management of breakthrough pain, as an application 
of nanotechnology, is an alternative method of systemic drug 
delivery, offering convenience in administration, improved 
absorption and pharmacokinetics (rapid onset of action bypassing 
gastrointestinal tract, and ﬁ  rst-pass metabolism in the liver), 
and thus better patient compliance and overall efﬁ  cacy. 
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